U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06819319) titled 'SHR-A2102 Combined with Adebrelimab As Neoadjuvant Therapy for Early Triple-Negative Breast Cancer' on Feb. 05.
Brief Summary: This is a prospective, open-label, multicenter Phase II study evaluating the efficacy and safety of of SHR-A2102 in combination with Adebrelimab in Early Triple-Negative Breast Cancer(TNBC)
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
TNBC - Triple-Negative Breast Cancer
Intervention:
DRUG: SHR-A2102 ; Adebrelimab injection
SHR-A2102 is administered intravenously, Adebrelimab is administered intravenously
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Henan Cancer Hospital
Info...